Nothing Special   »   [go: up one dir, main page]

EP2218444A3 - Rasagilinformulierung mit verzögerter Freisetzung - Google Patents

Rasagilinformulierung mit verzögerter Freisetzung Download PDF

Info

Publication number
EP2218444A3
EP2218444A3 EP10151462A EP10151462A EP2218444A3 EP 2218444 A3 EP2218444 A3 EP 2218444A3 EP 10151462 A EP10151462 A EP 10151462A EP 10151462 A EP10151462 A EP 10151462A EP 2218444 A3 EP2218444 A3 EP 2218444A3
Authority
EP
European Patent Office
Prior art keywords
delayed release
release rasagiline
rasagiline
formulation
rasagiline formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10151462A
Other languages
English (en)
French (fr)
Other versions
EP2218444A2 (de
Inventor
Muhammad Safadi
Daniella Licht
Rachel Cohen
Anton Frenkel
Marina Zholkovsky
Tamas Koltai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/455,976 external-priority patent/US8080584B2/en
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to PL10166534T priority Critical patent/PL2246321T3/pl
Priority to EP10166534A priority patent/EP2246321B1/de
Priority to DK10166534.7T priority patent/DK2246321T3/da
Priority to PL10186379T priority patent/PL2308477T3/pl
Priority to DK10186379.3T priority patent/DK2308477T3/da
Priority to EP10186379A priority patent/EP2308477B1/de
Publication of EP2218444A2 publication Critical patent/EP2218444A2/de
Publication of EP2218444A3 publication Critical patent/EP2218444A3/de
Priority to CZ201123855U priority patent/CZ22819U1/cs
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP10151462A 2009-01-23 2010-01-22 Rasagilinformulierung mit verzögerter Freisetzung Withdrawn EP2218444A3 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL10166534T PL2246321T3 (pl) 2009-01-23 2010-01-22 Formulacja rasagiliny o opóźnionym uwalnianiu
EP10166534A EP2246321B1 (de) 2009-01-23 2010-01-22 Rasagilinformulierung mit verzögerter Freisetzung
DK10166534.7T DK2246321T3 (da) 2009-01-23 2010-01-22 Rasagilinformulering med forsinket frisætning
PL10186379T PL2308477T3 (pl) 2009-01-23 2010-01-22 Formulacja rasagiliny o opóźnionym uwalnianiu
DK10186379.3T DK2308477T3 (da) 2009-01-23 2010-01-22 Rasagilinformulering med forsinket frisætning
EP10186379A EP2308477B1 (de) 2009-01-23 2010-01-22 Rasagilinformulierung mit verzögerter Freisetzung
CZ201123855U CZ22819U1 (cs) 2009-01-23 2011-01-27 Stabilní perorální léková forma s retardovaným uvolnováním rasagilinu

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20583309P 2009-01-23 2009-01-23
US12/455,976 US8080584B2 (en) 2009-01-23 2009-06-09 Delayed release rasagiline citrate formulation
US12/456,001 US20100189791A1 (en) 2009-01-23 2009-06-09 Delayed release rasagiline malate formulation
US12/456,029 US20100189790A1 (en) 2009-01-23 2009-06-09 Delayed release rasagiline formulation
US12/456,031 US20100189788A1 (en) 2009-01-23 2009-06-09 Delayed release rasagiline base formulation
US12/689,044 US7855233B2 (en) 2009-01-23 2010-01-18 Citrate salt of Rasagiline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10166534.7 Division-Into 2010-06-18

Publications (2)

Publication Number Publication Date
EP2218444A2 EP2218444A2 (de) 2010-08-18
EP2218444A3 true EP2218444A3 (de) 2010-08-25

Family

ID=42063279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10151462A Withdrawn EP2218444A3 (de) 2009-01-23 2010-01-22 Rasagilinformulierung mit verzögerter Freisetzung

Country Status (1)

Country Link
EP (1) EP2218444A3 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2531181T3 (da) 2010-02-03 2019-07-15 Pharma Two B Ltd Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
EP2598136A4 (de) * 2010-07-27 2015-03-25 Teva Pharma Dispersionen von rasagilincitrat
WO2013175493A1 (en) * 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2013182625A1 (en) * 2012-06-08 2013-12-12 Actavis Group Ptc Ehf Pharmaceutical formulation with propargylamine compound
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US11701340B2 (en) * 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093495A1 (en) * 2003-04-11 2007-04-26 Fariello Ruggero Methods for treatment of parkinson's disease
US20070112217A1 (en) * 2005-11-17 2007-05-17 Anton Frenkel Methods for isolating propargylated aminoindans
US20100010098A1 (en) * 2008-07-11 2010-01-14 Walter Elffrink Polymorphs of rasagiline hydrochloride

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
AU2005269416B2 (en) 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
AU2005309817B2 (en) 2004-11-24 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
RS52784B (en) 2006-12-14 2013-10-31 Teva Pharmaceutical Industries Ltd. They're TANATE RAZAGILINA
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093495A1 (en) * 2003-04-11 2007-04-26 Fariello Ruggero Methods for treatment of parkinson's disease
US20070112217A1 (en) * 2005-11-17 2007-05-17 Anton Frenkel Methods for isolating propargylated aminoindans
US20100010098A1 (en) * 2008-07-11 2010-01-14 Walter Elffrink Polymorphs of rasagiline hydrochloride

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A Controlled Trial of Rasagiline in Early Parkinson Disease. The TEMPO Study", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 59, 1 December 2002 (2002-12-01), pages 1937 - 1943, XP009132063, ISSN: 0003-9942 *
GOULD P L: "SALT SELECTION FOR BASIC DRUGS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL LNKD- DOI:10.1016/0378-5173(86)90055-4, vol. 33, no. 1/03, 1 January 1986 (1986-01-01), pages 201 - 217, XP002074725, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
EP2218444A2 (de) 2010-08-18

Similar Documents

Publication Publication Date Title
IL208858A (en) Formulations containing fats, methods of selecting and manufacturing and using them
WO2011130615A3 (en) Preparation of lacosamide
DK201100050U4 (da) Rasagilinformulering med forsinket frigivelse
IL219865A0 (en) Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
EP2568954A4 (de) Duftstoffformulierungen, verfahren zu ihrer herstellung und artikel damit
MX2010007601A (es) Formulaciones de rasagilina, su preparacion y uso.
IL238395B (en) Soluble attachment components of human serum, preparations and methods for their production
IL225637A0 (en) The compositions, tablets containing such compositions, their use and a process for their preparation
PL2393852T3 (pl) Polimery i kompozycje na bazie etylenu, sposoby ich wytwarzania oraz wytworzone z nich wyroby
WO2011093832A3 (en) Stable efervescent formulations comprising cefaclor
EP3626253A3 (de) Stabile linaclotidformulierungen
WO2010117738A3 (en) Solid state forms of sitagliptin salts
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
IL218370A0 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen, processes for producing the same and uses thereof
HK1162262A1 (zh) 基料、含有該基料的產物、其製備方法及用途
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
EP2218444A3 (de) Rasagilinformulierung mit verzögerter Freisetzung
WO2011069076A3 (en) Sustained release donepezil formulations
EP2562197A4 (de) Copolymer mit anthracen und enzoselenadiazol, herstellungsverfahren und verwendung
WO2009094457A3 (en) Substituted benzhydrylethers
EP2386553A4 (de) Benzimidazol-4-carboxamidderivate, ihr herstellungsverfahren, pharmazeutische zusammensetzungen und ihre verwendung
EP2361907A4 (de) Fünf kristallformen von nicousamid, herstellungsverfahren, pharmazeutische zusammensetzungen und uhre verwendung
WO2011045774A3 (en) Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
WO2009151770A3 (en) Colchicine solid-state forms; methods of making; and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 20100218

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147203

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/135 20060101ALI20110720BHEP

Ipc: A61K 9/20 20060101AFI20110720BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147203

Country of ref document: HK